English | Español
Amanda Rupp | Mar 11, 2016

Amgen submits supplemental Biologics License Application for Blincyto treatment

Amanda Rupp | Mar 11, 2016

ALS Association invests in new proposals for ALS treatment developments
Jamie Barrand | Mar 11, 2016

Opdivo under consideration in Europe for new indications
Jeff Gantt | Mar 10, 2016

TiGenix’s Cx601 trial shows positive results
Vimbai Chikomo | Mar 10, 2016

HHS estimates 43,000 have lost Obamacare tax credit after failing to file 2014 returns
Kerry Goff | Mar 10, 2016

Aetna says Hep C coverage likely to expand with new research
Jamie Barrand | Mar 9, 2016

FDA approves Imbruvica as first-line therapy for chronic lymphocytic leukemia
Jamie Barrand | Mar 9, 2016

University of Cincinnati using genetic clues from Black Plague to develop HIV therapies

Trending
+ Pharmaceuticals
Patient Daily | Sep 23, 2025

Wall Street Journal editorial board alleges hospitals misuse 340B program
+ Pharmaceuticals
Patient Daily | Sep 22, 2025

Nurses United for Healthcare Integrity says hospitals abuse 340B drug pricing program
+ Pharmaceuticals
Patient Daily | Sep 22, 2025

Staff Attorney of Legal Aid Society on 340B: 'Hospitals are exploiting the 340B program'
+ Marketing
Patient Daily | Sep 17, 2025

Patients Come First spokesperson: Drug ads 'are putting lives at risk by encouraging people to abandon essential treatments'